EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Hidalgo-Tenorio, Carmen
  • dc.contributor.author Sadyrbaeva-Dolgova, Svetlana
  • dc.contributor.author Enríquez-Gómez, Andrés
  • dc.contributor.author Muñoz-Millán, Patricia
  • dc.contributor.author Plata Ciézar, Antonio
  • dc.contributor.author Miró, José María
  • dc.contributor.author Alarcón, Arístides
  • dc.contributor.author Martínez-Marcos, Francisco Javier
  • dc.contributor.author Loeches, Belén
  • dc.contributor.author Escrihuela-Vidal, Francesc
  • dc.contributor.author Vinuesa, David
  • dc.contributor.author Herrero, Carmen
  • dc.contributor.author Boix Palop, Lucía
  • dc.contributor.author Arenas Miras, María del Mar
  • dc.contributor.author García Vázquez, Elisa
  • dc.contributor.author Arnaiz de las Revillas, Francisco
  • dc.contributor.author Pasquau, Juan
  • dc.contributor.author EN-DALBACEN study group
  • dc.date.accessioned 2024-05-17T05:45:24Z
  • dc.date.available 2024-05-17T05:45:24Z
  • dc.date.issued 2023
  • dc.description.abstract Objectives: Infective endocarditis (IE) has high mortality and morbidity and requires long hospital stays to deliver the antibiotic treatment recommended in clinical practice guidelines. We aimed to analyse the health outcomes of the use of dalbavancin (DBV) in the consolidation treatment of IEs caused by Gram-positive cocci and to perform a pharmacoeconomic study. Materials and methods: This observational, retrospective, Spanish multicentre study in patients with IE who received DBV as part of antibiotic treatment in consolidation phase were followed for at least 12 months. The study was approved by the Provincial Committee of the coordinating centre. Results: The study included 124 subjects, 70.2% male, with a mean age of 67.4 years and median Charlson index of 4 (interquartile range: 2.5-6). Criteria for definite IE were met by 91.1%. Coagulase-negative staphylococci (38.8%), Staphylococcus aureus (22.6%), Enterococcus faecalis (19.4%), and Streptococcus Spp. (9.7%) were isolated more frequently, all susceptible to vancomycin. Before DVB administration, 91.2% had undergone surgery; 60.5% had received a second regimen for 24.5 d (16.6-56); and 20.2% had received a third regimen for 14.5 d (12-19.5). DBV was administered to facilitate discharge in 95.2% of cases. At 12 months, the effectiveness was of 95.9%, and there was 0.8% loss to follow-up, 0.8% IE-related death, and 3.2% relapse. Adverse events were recorded in 3.2%. The hospital stay was reduced by 14 d, and there was a mean savings of 5548.57 €/patient vs. conventional treatments. Conclusion: DBV is highly effective, safe, and cost-effective as consolidation therapy in patients with IE by Gram-positive cocci, with few adverse events.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Hidalgo-Tenorio C, Sadyrbaeva-Dolgova S, Enríquez-Gómez A, Muñoz P, Plata-Ciezar A, Miró JM, et al. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci. Int J Antimicrob Agents. 2023 Sep;62(3):106918. DOI: 10.1016/j.ijantimicag.2023.106918
  • dc.identifier.doi http://dx.doi.org/10.1016/j.ijantimicag.2023.106918
  • dc.identifier.issn 0924-8579
  • dc.identifier.uri http://hdl.handle.net/10230/60175
  • dc.language.iso eng
  • dc.publisher Elsevier
  • dc.relation.ispartof Int J Antimicrob Agents. 2023 Sep;62(3):106918
  • dc.rights © 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
  • dc.subject.keyword Cost-effective
  • dc.subject.keyword Dalbavancin
  • dc.subject.keyword Endocarditis
  • dc.title EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)